Comparing surgical treatment outcomes in patients with different lung diseases and breathing tube repair types

Broncho-Pleural Complications after Pneumonectomy depending on the disease and the bronchial suture type. Retrospective observational study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN17157026

Enrollment

2001

Registered

2021-09-20

Start date

1959-11-14

Completion date

Unknown

Last updated

2021-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonectomy for pulmonary cancer, tuberculosis or nonspecific chronic inflammatory lung diseases. Surgery

Interventions

Patients who underwent pneumonectomy due to tuberculosis, oncology, or nonspecific chronic inflammatory disease are included in this trial. They have undergone treatment according to their disease and

culture method)

- Morphological, histological and cytological examination of biopsy material - Methods of statistical data processing.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who have had a pneumonectomy from 1959 to 2021 at the following institutions: 1. State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical Anti-Tuberculosis Dispensary" 38, Vorovskogo str., Chelyabinsk, Russian Federation, 454092. From 1959 to 2004 2. Central TB Research Institute, 2, Yauzskaya alley, Moscow, Russian Federation, 107564 From 2004-2011 3. Sechenov University Phthisiopulmonology Clinical Hospital, 4, Dostoevskogo str., Moscow, Russian Federation, 127473. From 2011 to 2017 4. Ingush Republican TB Dispensary, 1, Bolnichnaya str., Plievo Village, Nazranovsky District, Republic of Ingushetia, Russian Federation, 386124. From 2018 to 2021 5. Regional Clinical Tuberculosis Dispensary, 22, Volskaya str., Saratov, Russian Federation, 410056. From 2018 to 2021 6. JSC «MEDICINE» (CLINIC OF ACADEMICIAN ROYTBERG), 10, 2nd Tverskoy-Yamskoy Pereulok, Moscow, Russian Federation, 125047. From 2018 to 2021

Exclusion criteria

Exclusion criteria: 1. Patients admitted before 14/11/1959 and after 01/09/2021 2. Patients who passed lung resections in volume less than pneumonectomy

Design outcomes

Primary

Measure	Time frame
Measured retrospectively using patient records: 1. Bronchopleural fistula development 2. 30-day postoperative mortality rate 3. Postoperative long term bronchopleural complications 4. Postoperative mortality due to bronchopleural complications	—

Secondary

Measure	Time frame
Measured retrospectively using patient records: 1. Surgery efficacy in patients with tuberculosis measured using 1.1. Sputum culture conversion rate after surgery and one, three and five years after surgery 1.2. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray on discharge from the hospital, one, three and five years post-surgery. 2. Surgery efficacy in oncology patients measured using 2.1. Clear resections edges 2.2. R0 resection 2.3. 5-year survival rate 3. Surgery efficacy in patients with nonspecific chronical inflammatory lung diseases measured using absence of inflammatory process according to microbiological, roentgenological and clinical analysis after surgery and one, three and five years after surgery. 4. Five-year survival rate	—

Measure

Time frame

Measured retrospectively using patient records: 1. Surgery efficacy in patients with tuberculosis measured using 1.1. Sputum culture conversion rate after surgery and one, three and five years after surgery 1.2. Presence of cavities in pulmonary tissue (CV+/CV-) determined with CT scan/digital X-ray on discharge from the hospital, one, three and five years post-surgery. 2. Surgery efficacy in oncology patients measured using 2.1. Clear resections edges 2.2. R0 resection 2.3. 5-year survival rate 3. Surgery efficacy in patients with nonspecific chronical inflammatory lung diseases measured using absence of inflammatory process according to microbiological, roentgenological and clinical analysis after surgery and one, three and five years after surgery. 4. Five-year survival rate

—

Countries

Russian Federation

Contacts

Public ContactDmitry Giller

giller-thorax@mail.ru+7 9168681291

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026